Japanese Government Procurement
National University Corporation - Notice of Procurement (Goods & Services)Agalsidase beta (Genetical Recombination) for Injection 35mg/Vial 60cases,and 17 other contracts
This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.
| Publishing date | Jan 26, 2026 |
|---|---|
| Type of notice | Notice of Procurement (Goods & Services) |
| Procurement entity | National University Corporation - Fukui |
| Classification |
0004 Medical & Pharmaceutical Products |
| Summay of notice | ⑴ Official in charge of disbursement of the procuring entity : Dou Yuji, The Obligating Officer Director of Finance Department, University of Fukui ⑵ Classification of the products to be procured : 4 ⑶ Nature and quantity of the products to be purchased : A Agalsidase beta (Genetical Recombination) for Injection 35mg/Vial 60cases B Axicabtagene ciloleucel 1bag 1case C Atezolizumab (Genetical Recombination) Injection 1,200mg20mL/Vial 248cases D Inotuzumab ozogamicin (Genetical Recombination) for Injection 1mg/Vial 24cases E Emicizumab (Genetical Recombination) Injection 150mg1mL/Vial 24cases F Onasemnogene abeparvovec 1 Patient Dose 1case G Satralizumab (Genetical Recombination) Kit 120mg1mL/Syringe 50cases H Cetuximab (Genetical Recombination) Injection 100mg20mL/Vial 1,506cases Ⅰ Teprotumumab (Genetical Recombination) for Injection 500mg/Vial 26cases J Pabinafusp Alfa (Genetical Recombination) for Injection 10mg/Vial 460cases K Human (autologous) Bone Marrow-Derived mesenchymal stem cells 1 Dose 2cases L Faricimab (Genetical Recombination) Kit 6mg0.05mL/Syringe 352cases M Vutrisiran Sodium Kit 25mg0.5mL/Syringe 12cases N Pegfilgrastim (Genetical Recombination) Kit 3.6mg0.36mL/Syringe 388cases O Pertuzumab (Genetical Recombination)･Trastuzumab (Genetical Recombination)･Vorhyaluronidase alfa (Genetical Recombination) Injection 10mL/Vial 258cases P Polatuzumab Vedotin (Genetical Recombination) for Injection 30mg/Vial 322cases Q Ravulizumab (Genetical Recombination) Injection 1100mg11mL/Vial 18cases R Remdesivir for Injection 100mg/Vial 440cases ⑷ Delivery period : From 1 April, 2026 through 31 March, 2027 ⑸ Delivery place : University of Fukui Hospital ⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article 6 of the Regulation concerning the Contract for University of Fukui Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause, B have the Grade A, Grade B or Grade C qualification during fiscal 2025 in the Tokai・Hokuriku area in sales of product for participating in tenders by Single qualification for every ministry and agency, C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices, D prove to have the ability to deliver the products, required by this notice, on the date and the place specified by the Obligating Officer, E not be currently under a suspension of business order as instructed by The Obligating Officer. ⑺ Time limit of tender : 17 : 00 18 March, 2026 ⑻ Contact point for the notice : Akihiro Igarashi, Procurement Section, Accounting Division, Finance Department, University of Fukui, 23-3 Matsuokashimoaizuki Eiheiji-cho Yoshida-gun Fukui 910-1193 Japan, TEL 0776-61-3111 ex. 3145 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents. |
